General
Preferred name
NORFLOXACIN
Synonyms
Norfloxacin (hydrochloride) ()
MK-0366 (hydrochloride) ()
MK-0366 ()
Norfloxacin (Norxacin) ()
Norfloxacin Hydrochloride ()
Baccidal ()
Noroxin ()
Chibroxin ()
NSC-757250 ()
Utinor ()
Quinabic ()
MK-366 ()
Norfloxacin-d5 ()
P&D ID
PD001831
CAS
70458-96-7
68077-27-0
1015856-57-1
Tags
natural product
drug
available
Approved by
FDA
First approval
1986
Drug Status
approved
Drug indication
Bacterial infection
Antibacterial
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE Norfloxacin is eliminated through metabolism, biliary excretion, and renal excretion. It is expected to undergo both glomerular filtration and tubular secretion during renal excretion, as shown by its high renal clearance rate of approximately 275 mL/min.
DESCRIPTION Norfloxacin is a fluoroquinolone compound with broad-spectrum antibacterial activity . (GtoPdb)
MOA The bactericidal action of Norfloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. Norfloxacin is a broad-spectrum antibiotic agent that is shown to be effective against various Gram-positive and Gram-negative bacterial species. The fluorine atom at the 6 position increases potency against gram-negative organisms, and the piperazine moiety at the 7 position is responsible for anti-pseudomonal activity
DESCRIPTION Norfloxacin hydrochloride is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria, which functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase IV, enzymes necessary to separate bacterial DNA, thereby inhibiting cell division. It is a synthetic chemotherapeutic antibacterial agent occasionally used to treat common as well as complicated urinary tract infections. (BOC Sciences Bioactive Compounds)
Cell lines
6
Organisms
3
Compound Sets
23
AdooQ Bioactive Compound Library
A10652
BOC Sciences Bioactive Compounds
norfloxacin-hydrochloride-cas-68077-27-0-147992
Cayman Chemical Bioactives
25975
28521
ChEMBL Approved Drugs
CHEMBL9
ChEMBL Drugs
CHEMBL9
Drug Repurposing Hub
DrugBank
DB01059
DrugBank Approved Drugs
DB01059
DrugCentral
1967
DrugCentral Approved Drugs
1967
DrugMAP
DMIZ6W2
DrugMAP Approved Drugs
DMIZ6W2
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS100573
Guide to Pharmacology
12408
MedChem Express Bioactive Compound Library
HY-B0132
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Norfloxacin(Norxacin)
TargetMol Bioactive Compound Library
T1306
The Spectrum Collection
External IDs
53
Properties
(calculated by RDKit )
Molecular Weight
319.13
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
3
Aromatic Ring Count
2
cLogP
1.27
TPSA
74.57
Fraction CSP3
0.38
Chiral centers
0.0
Largest ring
6.0
QED
0.89
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Bacterial
DNA gyrase
Topo II
TOP2A
antibiotic
Endogenous Metabolite
Topoisomerase
Pathway
Anti-infection
DNA Damage/DNA Repair
Metabolic Enzyme/Protease
Indication
urinary tract infections, gonorrhea, prostatitis
Disease Area
infectious disease, urology
MOA
bacterial DNA gyrase inhibitor
Therapeutic Class
Antibiotics
Source data